US intuitive hand in hand Fosun medicinal surgery robot new line landing in China
On December 10, Fosun Pharma and US Intuition officially announced the launch of strategic cooperation between the two parties in China, jointly invested US$100 million to establish a joint venture in Shanghai, researching, developing, manufacturing and selling innovations based on robot-assisted catheter technology for early diagnosis and treatment of lung cancer. product. The new company is expected to settle in Shanghai Zhangjiang.
US intuitive hand in hand Fosun medicinal surgery robot new line landing in China
The originator of the surgical robot, the American Intuitive Medical Device Company, decided to place its new product line layout in addition to the Da Vinci surgical robot in China.On December 10, Fosun Pharma and IntuiTIve Surgical officially announced the launch of their strategic cooperation in China, jointly investing US$100 million to establish a joint venture in Shanghai to develop, produce and sell innovative robotic-assisted catheter technology for early diagnosis and treatment of lung cancer. product. The new company is expected to settle in Shanghai Zhangjiang.
This is not the first cooperation between the two parties. Since 2011, Fosun Pharma's subsidiary, US-China Mutual Medical Co., Ltd., has been responsible for the exclusive distribution of Da Vinci surgical robots in China. It is the Da Vinci surgical robot that has created IntuiTIve Surgical's more than 4,000 patents today with a market capitalization of $25 billion.
The new product is still in development. The partners revealed that in terms of technology, the products will use natural airways to enter the lungs, combined with advanced technologies such as CT image planning system for diagnosis and minimally invasive surgery, thus helping patients to effectively diagnose or even cure at an early stage. Initial product development will focus on the early diagnosis of lung cancer, followed by an effective treatment for early stage lung cancer. This is the new product line layout of IntuiTIve Surgical in addition to the Da Vinci surgical robot.
At present, lung cancer is the leading cancer disease in China. Worldwide, lung cancer is also considered to be the most deadly cancer disease, and one out of every five cancer-causing patients has died of lung cancer.
In addition to the high mortality rate of lung cancer in China, the market potential of Da Vinci surgical robots in China reflects the market's most important reason for IntuiTIve Surgical to bring this new lung cancer product from Silicon Valley to China.
The Da Vinci Surgical Robot, launched in the United States in 2000, is an advanced robotic platform designed to perform complex surgical procedures using minimally invasive methods. Compared with open surgery, minimally invasive surgery has obvious advantages in terms of postoperative recovery, wound anti-infection, and avoidance of reoperation because of smaller incision and more precise surgical procedures. At present, Da Vinci surgical robots can be used in general surgery, thoracic surgery, urology, obstetrics and gynecology, head and neck surgery, and heart surgery for adults and children.
The Da Vinci surgical robot was introduced to China in 2006, and this technology has shown amazing efficiency in China. According to Chen Qiyu, chairman of Fosun Pharma, 37 Da Vinci robots in mainland China last year achieved the operation of 200 machines in Japan.
Currently, there are 69 Da Vinci surgical robots in mainland China and Hong Kong, accounting for only 2% of the global total. Limiting the amount of this advanced robotic platform in the Chinese market is not the high price of 20 million yuan, but the approval and regulation of the government. Chen Qiyu revealed that since the deployment of the 12th Five-Year Plan was loosened, the growth rate of Da Vinci surgical robots has accelerated significantly in the past two years. In fact, 2,500 of the more than 3,000 machines in the world are currently in the United States.
The strategic ambition of Fosun Pharma is also the driving force behind the development of the cooperation between the two sides from the distribution cooperation to research and development cooperation. As a giant in China's medical and health industry, Fosun, the finger of “China's Johnson & Johnsonâ€, has been working hard to build a medical health industry chain. Medical devices are an important part of its industrial chain.
Chen Qiyu described the cooperation as "the source of innovation in the United States + the low-cost incubation of China." He believes that the current source of innovation in the field of medical devices is still in the United States, and China has become a low-cost innovation incubator for rapid advancement and large-scale production with its large number of scientific and technical personnel, clinical data sources and medical market potential.
In recent years, Fosun Pharma's sweeping of goods in the field of medical devices has not been confined to the United States. In 2013, Fosun Pharma acquired a 95.2% stake in Alma Lasers, a well-known Israeli medical and beauty equipment manufacturer. Similar to Intuitive Surgical's cooperation, Chen Qiyu said that Fosun will continue to adopt a “two-headed†strategy. On the one hand, the sales team will use the market to cultivate and maintain market access for international high-tech products, and on the other hand, continue to seek globally. The source of technological innovation.
In 2016, Fosun’s semi-annual report showed that medical device agents achieved the largest revenue growth in all businesses, up 31.41% year-on-year. According to the financial report, because the amount of Da Vinci surgical robot surgery increased rapidly in the first half of this year, it led to an increase in sales of consumables and an increase in operating income. Detailed data shows that Da Vinci surgical robots have about 8,000 operations in mainland China and Hong Kong, an increase of about 49% year-on-year.
Whether the new products that cooperate with Intuitive Surgical in the future can bring considerable benefits to Fosun Pharma like the Da Vinci robot. Chen Qiyu said that due to its strong learning ability and reproducibility, artificial intelligence will definitely replace the scarce doctor resources in a wide range of applications in the future. Relying on Intuitive Surgical, the technical core of this new product will be very leading and the market prospect is broad, but the current work is still the initial investment of several years, including the construction of the company management system, the establishment of the factory, and the promotion of product approval. “Taking the Da Vinci robot as an example, since the introduction of the first Da Vinci robot in China in 2006, the first seven or eight years of these 10 years have been net investment periods, including doctors’ education and training, brand image building, and continuous Clinical application and research, etc., have only tasted the sweetness in the past two years."
The product are CS601 Digital Pressure Gauge, CS108 Digital Pressure Gauge, CS602 Intelligent Pressure Calibrator.
Pressure Gauge Calibration Standard,Pressure Gauge Calibration Equipment,Pressure Gauge Calibration Services,Digital Pressure Calibrator
Changshu Herun Import & Export Co.,Ltd , https://www.herunchina.com